Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) was up 8.1% during mid-day trading on Friday . The company traded as high as $9.80 and last traded at $9.76. Approximately 577,913 shares traded hands during trading, a decline of 52% from the average daily volume of 1,204,282 shares. The stock had previously closed at $9.03.
Analyst Ratings Changes
Several research analysts recently issued reports on AVXL shares. D. Boral Capital reiterated a "buy" rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research report on Monday, November 25th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Anavex Life Sciences in a report on Wednesday.
Get Our Latest Analysis on AVXL
Anavex Life Sciences Price Performance
The stock has a market capitalization of $802.17 million, a PE ratio of -18.92 and a beta of 0.60. The firm's 50 day simple moving average is $6.75 and its 200 day simple moving average is $5.71.
Institutional Trading of Anavex Life Sciences
Several institutional investors have recently added to or reduced their stakes in AVXL. Renaissance Technologies LLC boosted its stake in shares of Anavex Life Sciences by 483.8% during the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company's stock valued at $1,968,000 after purchasing an additional 386,537 shares during the period. Virtu Financial LLC boosted its position in Anavex Life Sciences by 87.5% during the 1st quarter. Virtu Financial LLC now owns 40,612 shares of the biotechnology company's stock valued at $207,000 after buying an additional 18,954 shares during the period. Nwam LLC bought a new stake in Anavex Life Sciences in the 3rd quarter worth $5,172,000. Deerfield Management Company L.P. Series C purchased a new position in shares of Anavex Life Sciences in the second quarter valued at about $346,000. Finally, Vanguard Group Inc. raised its stake in shares of Anavex Life Sciences by 1.2% during the first quarter. Vanguard Group Inc. now owns 4,414,682 shares of the biotechnology company's stock valued at $22,471,000 after acquiring an additional 54,034 shares during the last quarter. 31.55% of the stock is currently owned by hedge funds and other institutional investors.
About Anavex Life Sciences
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
See Also
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
